LUND, Sweden, March 26, 2020 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia") announced today that current Board Member,
Hans Johansson, has acquired
Immunovia shares for 500 KSEK on the open market and his total
holding is now 28542 shares.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
For more information, please contact:
Julie Silber, Director of
Investor Relations
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
The information was submitted for publication, through the
agency of the contact person set out above, at 14:00 CET on March 26,
2020.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/board-member-hans-johansson-buys-immunovia-shares,c3069536
The following files are available for download:
https://mb.cision.com/Main/13121/3069536/1218407.pdf
|
Release
|